+ Follow BRISTOL-MYERS SQUIBB CO Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1265295
[Title] => FDA approves breakthrough hepatitis C drug
[Summary] => Federal health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
[DatePublished] => 2013-12-07 07:32:52
[ColumnID] => 0
[Focus] => 0
[AuthorID] => 1510054
[AuthorName] => Matthew Perrone
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img4.imageshack.us/img4/181/l7wd.jpg
)
[1] => Array
(
[ArticleID] => 1210031
[Title] => Bristol-Myers skin cancer drug Yervoy misses goal in study of additional, prostate cancer use
[Summary] => Bristol-Myers Squibb Co.'s skin cancer treatment Yervoy missed a main goal of achieving a significant improvement in overall survival compared to a fake drug when tested in patients with an advanced form of prostate cancer, the drugmaker said Thursday.
[DatePublished] => 2013-09-14 06:11:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img842.imageshack.us/img842/7071/3hew.jpg
)
[2] => Array
(
[ArticleID] => 843985
[Title] => Bristol-Myers recalls vials of cancer drug
[Summary] => Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.
[DatePublished] => 2012-08-31 09:05:48
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[3] => Array
(
[ArticleID] => 843976
[Title] => Bristol-Myers recalls vials of cancer drug
[Summary] => Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.
[DatePublished] => 2012-08-31 01:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[4] => Array
(
[ArticleID] => 644450
[Title] => Tough anti-trust law pushed
[Summary] => Cebu Rep. Eduardo Gullas is urging his colleagues in Congress to a new and potent anti-trust law that would protect consumers as well as businesses from wrongful and unfair methods of competition in commerce.
[DatePublished] => 2011-01-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] => 1097047
[AuthorName] => Jess Diaz
[SectionName] => Headlines
[SectionUrl] => headlines
[URL] =>
)
[5] => Array
(
[ArticleID] => 500706
[Title] => New AstraZeneca drug reduces heart patients' risks
[Summary] => A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says.
[DatePublished] => 2009-08-31 02:33:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 424960
[Title] => GLOBAL NEWS: Oil rises slightly after sharp drop overnight
[Summary] => SINGAPORE (AP) — Oil prices rose slightly Friday in Asia after a sharp decline overnight as investors mulled how much the global economic slowdown will dampen crude demand.
[DatePublished] => 2008-12-19 12:59:11
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[7] => Array
(
[ArticleID] => 326517
[Title] => FDA grants priority review to new drug for acute STEMI
[Summary] => Sanofi-aventis and Bristol-Myers Squibb Co. announced recently that the US Food and Drug Administration (FDA) has accepted for review a supplemental new drug application for the antiplatelet agent clopidogrel bisulfate for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).
STEMI is a heart attack in which an artery is generally blocked completely for sufficient time to cause heart muscle damage. This blockage is caused by clot formation in the arteries, which is also known as atherothrombosis.
[DatePublished] => 2006-03-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 176597
[Title] => Clinical trial on ‘HF-PSF’ underway
[Summary] => BERLIN, Germany – The launch of a new landmark clinical study, I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function), was recently announced at the European Society of Cardiology meeting by its principal investigators, Drs. Peter Carson and Barry Massie, on behalf of the I-PRESERVE study steering committee.
The I-PRESERVE study is supported by a grant from Bristol-Myers Squibb Co. and Sanofi-Synthelabo Inc.
[DatePublished] => 2002-09-19 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
BRISTOL-MYERS SQUIBB CO
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1265295
[Title] => FDA approves breakthrough hepatitis C drug
[Summary] => Federal health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
[DatePublished] => 2013-12-07 07:32:52
[ColumnID] => 0
[Focus] => 0
[AuthorID] => 1510054
[AuthorName] => Matthew Perrone
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img4.imageshack.us/img4/181/l7wd.jpg
)
[1] => Array
(
[ArticleID] => 1210031
[Title] => Bristol-Myers skin cancer drug Yervoy misses goal in study of additional, prostate cancer use
[Summary] => Bristol-Myers Squibb Co.'s skin cancer treatment Yervoy missed a main goal of achieving a significant improvement in overall survival compared to a fake drug when tested in patients with an advanced form of prostate cancer, the drugmaker said Thursday.
[DatePublished] => 2013-09-14 06:11:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img842.imageshack.us/img842/7071/3hew.jpg
)
[2] => Array
(
[ArticleID] => 843985
[Title] => Bristol-Myers recalls vials of cancer drug
[Summary] => Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.
[DatePublished] => 2012-08-31 09:05:48
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[3] => Array
(
[ArticleID] => 843976
[Title] => Bristol-Myers recalls vials of cancer drug
[Summary] => Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.
[DatePublished] => 2012-08-31 01:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[4] => Array
(
[ArticleID] => 644450
[Title] => Tough anti-trust law pushed
[Summary] => Cebu Rep. Eduardo Gullas is urging his colleagues in Congress to a new and potent anti-trust law that would protect consumers as well as businesses from wrongful and unfair methods of competition in commerce.
[DatePublished] => 2011-01-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] => 1097047
[AuthorName] => Jess Diaz
[SectionName] => Headlines
[SectionUrl] => headlines
[URL] =>
)
[5] => Array
(
[ArticleID] => 500706
[Title] => New AstraZeneca drug reduces heart patients' risks
[Summary] => A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says.
[DatePublished] => 2009-08-31 02:33:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 424960
[Title] => GLOBAL NEWS: Oil rises slightly after sharp drop overnight
[Summary] => SINGAPORE (AP) — Oil prices rose slightly Friday in Asia after a sharp decline overnight as investors mulled how much the global economic slowdown will dampen crude demand.
[DatePublished] => 2008-12-19 12:59:11
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[7] => Array
(
[ArticleID] => 326517
[Title] => FDA grants priority review to new drug for acute STEMI
[Summary] => Sanofi-aventis and Bristol-Myers Squibb Co. announced recently that the US Food and Drug Administration (FDA) has accepted for review a supplemental new drug application for the antiplatelet agent clopidogrel bisulfate for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).
STEMI is a heart attack in which an artery is generally blocked completely for sufficient time to cause heart muscle damage. This blockage is caused by clot formation in the arteries, which is also known as atherothrombosis.
[DatePublished] => 2006-03-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 176597
[Title] => Clinical trial on ‘HF-PSF’ underway
[Summary] => BERLIN, Germany – The launch of a new landmark clinical study, I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function), was recently announced at the European Society of Cardiology meeting by its principal investigators, Drs. Peter Carson and Barry Massie, on behalf of the I-PRESERVE study steering committee.
The I-PRESERVE study is supported by a grant from Bristol-Myers Squibb Co. and Sanofi-Synthelabo Inc.
[DatePublished] => 2002-09-19 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
September 14, 2013 - 6:11am
December 19, 2008 - 12:59pm
September 19, 2002 - 12:00am
